Immunocytokines: A novel class of potent armed antibodies

Drug Discovery Today

Volumn 17, Issue 11-12, 2012, Pages 583-590

  Pasche, Nadine ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AS 1409; CYTOKINE; DACARBAZINE; DEKAVIL; DERLEUKIN; EMD 273063; EMD 521873; FIBROMUN; IMMUNOCYTOKINE; INTERLEUKIN 15; INTERLEUKIN 19; INTERLEUKIN 2; MSB 0010360; RECOMBINANT CYTOKINE; TELEUKIN; TUCOTUZUMAB CELMOLEUKIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; BREAST CANCER; COLORECTAL CANCER; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG HALF LIFE; ENDOMETRIOSIS; EPITHELIUM TUMOR; HUMAN; KIDNEY CARCINOMA; LIVER CLEARANCE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULAR WEIGHT; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PROSTATE CANCER; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MOLECULAR TARGETED THERAPY; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION;

EID: 84861610591     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.01.007     Document Type: Review

References (89)

1. G. Walsh Biopharmaceutical benchmarks 2010 Nat. Biotechnol. 28 2010 917 924
2. T. Aoki Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo Proc. Natl. Acad. Sci. U.S.A. 89 1992 3850 3854
3. S.E. Barker Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12 Br. J. Cancer 97 2007 210 217
4. C. Jackaman IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2 J. Immunol. 171 2003 5051 5063
5. Y. Koshita Efficacy of TNF-alpha gene-transduced tumor cells in treatment of established in vivo tumor Int. J. Cancer 63 1995 130 135
6. P.W. Miller Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication Hum. Gene Ther. 11 2000 53 65
7. J.C. Becker T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy J. Exp. Med. 183 1996 2361 2366
8. J.C. Becker Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins Proc. Natl. Acad. Sci. U.S.A. 93 1996 2702 2707
9. R. Xiang Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy Cancer Res. 57 1997 4948 4955
10. J.P. Leonard Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production Blood 90 1997 2541 2548
11. B. Carnemolla Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix Blood 99 2002 1659 1665
12. C. Halin Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature Nat. Biotechnol. 20 2002 264 269
13. D. Schrama Antibody targeted drugs as cancer therapeutics Nat. Rev. Drug Discov. 5 2006 147 159
14. D. Neri, and R. Bicknell Tumour vascular targeting Nat. Rev. Cancer 5 2005 436 446
15. D. Neri, and C.T. Supuran Interfering with pH regulation in tumours as a therapeutic strategy Nat. Rev. Drug Discov. 10 2011 767 777
16. B. Borgia A proteomic approach for the identification of vascular markers of liver metastasis Cancer Res. 70 2010 309 318
17. C. Schliemann In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy Blood 115 2010 736 744
18. P. Holliger 'Diabodies': small bivalent and bispecific antibody fragments Proc. Natl. Acad. Sci. U.S.A. 90 1993 6444 6448
19. L. Borsi Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin Int. J. Cancer 102 2002 75 85
20. A.M. Wu Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers Immunotechnology 2 1996 21 36
21. M.G. Rosenblum An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models Cancer Immunol. Immunother. 40 1995 322 328
22. E.A. Rossi CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas Blood 114 2009 3864 3871
23. E.A. Rossi Preclinical studies on targeted delivery of multiple IFNalpha2b to HLA-DR in diverse hematologic cancers Blood 118 2011 1877 1884
24. L. Borsi Selective targeted delivery of TNFalpha to tumor blood vessels Blood 102 2003 4384 4392
25. M. Kaspar The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis Cancer Res. 67 2007 4940 4948
26. N. Pasche Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7 J. Biotechnol. 154 2011 84 92
27. C. Ebbinghaus Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy Int. J. Cancer 116 2005 304 313
28. K. Schwager The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model Hum. Reprod. 26 2011 2344 2352
29. K. Schwager Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis Arthritis Res. Ther. 11 2009 R142
30. E. Trachsel Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis Arthritis Res. Ther. 9 2007 R9
31. E. Trachsel A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo J. Invest. Dermatol. 127 2007 881 886
32. S.A. Holden Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents Clin. Cancer Res. 7 2001 2862 2869
33. J. Marlind Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy Clin. Cancer Res. 14 2008 6515 6524
34. M. Pedretti Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma Br. J. Cancer 103 2010 827 836
35. C. Schliemann Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2 Blood 113 2009 2275 2283
36. C. Halin Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha Cancer Res. 63 2003 3202 3210
37. J.L. Hornick Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors Clin. Cancer Res. 5 1999 51 60
38. K. Frey Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation Integr. Biol. (Camb) 3 2011 468 478
39. E. Balza Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin Clin. Cancer Res. 12 2006 2575 2582
40. S.D. Gillies Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer Cancer Immunol. Immunother. 51 2002 449 460
41. M. Johannsen The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma Eur. J. Cancer. 46 2010 2926 2935
42. T.K. Eigentler A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma Clin. Cancer Res. 17 2011 7732 7742
43. D.M. King Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients J. Clin. Oncol. 22 2004 4463 4473
44. A. Ribas Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma J. Transl. Med. 7 2009 68
45. K.L. Osenga A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group Clin. Cancer Res. 12 2006 1750 1759
46. S. Shusterman Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study J. Clin. Oncol. 28 2010 4969 4975
47. Y.J. Ko Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer J. Immunother. 27 2004 232 239
48. J.C. Yang Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer J. Clin. Oncol. 21 2003 3127 3132
49. S.A. Rosenberg Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response Ann. Surg. 228 1998 307 319
50. G.I. Kirchner Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application Br. J. Clin. Pharmacol. 46 1998 5 10
51. S.M. Rudman A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma Clin. Cancer Res. 17 2011 1998 2005
52. B.M. Tijink (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy Eur. J. Nucl. Med. Mol. Imaging 36 2009 1235 1244
53. M. Bassani-Sternberg Soluble plasma HLA peptidome as a potential source for cancer biomarkers Proc. Natl. Acad. Sci. U.S.A. 107 2010 18769 18776
54. H.N. Lode Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy Blood 91 1998 1706 1715
55. S. Bauer Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein J. Immunol. 172 2004 3930 3939
56. S. Bauer Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg Int. J. Cancer 125 2009 115 123
57. Y. Liu Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor Int. J. Cancer 108 2004 549 557
58. Y. Liu The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts Neoplasia 8 2006 384 393
59. S.P. Cooke In vivo tumor delivery of a recombinant single chain Fv::tumor necrosis factor-alpha fusion [correction of factor: a fusion] protein Bioconjug. Chem. 13 2002 7 15
60. J. Sharifi Generation of human interferon gamma and tumor necrosis factor alpha chimeric TNT-3 fusion proteins Hybrid Hybridomics 21 2002 421 432
61. O. Christ Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy Clin. Cancer Res. 7 2001 985 998
62. U. Scherf Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells Clin. Cancer Res. 2 1996 1523 1531
63. J.S. Dela Cruz Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity J. Immunol. 165 2000 5112 5121
64. J.L. Hornick Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties Blood 89 1997 4437 4447
65. K. Frey The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma J. Urol. 184 2010 2540 2548
66. C.S. Dolman Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy Clin. Cancer Res. 4 1998 2551 2557
67. H.N. Lode Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow J. Natl. Cancer Inst. 89 1997 1586 1594
68. H. Sabzevari A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice Proc. Natl. Acad. Sci. U.S.A. 91 1994 9626 9630
69. Z.C. Neal Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy Clin. Cancer Res. 10 2004 4839 4847
70. J.C. Becker Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy J. Clin. Invest. 98 1996 2801 2804
71. J.D. Pancook Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2 Cancer Immunol. Immunother. 42 1996 88 92
72. S.D. Gillies An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma Blood 105 2005 3972 3978
73. M.L. Penichet A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors Hum. Antibodies 10 2001 43 49
74. X. Xu Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein Cancer Res. 60 2000 4475 4484
75. H. Matsumoto Targeting of interleukin-2 to human MK-1-expressing carcinoma by fusion with a single-chain Fv of anti-MK-1 antibody Anticancer Res. 22 2002 2001 2007
76. C. Melani Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody Cancer Res. 58 1998 4146 4154
77. X. Huang Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine Vaccine 29 2011 4785 4793
78. S.D. Gillies A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity Clin. Cancer Res. 17 2011 3673 3685
79. K.M. Lo huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models Cancer Immunol. Immunother. 56 2007 447 457
80. J. Li chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors Hybrid Hybridomics 23 2004 1 10
81. S.D. Gillies Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases J. Immunol. 160 1998 6195 6203
82. L.S. Peng A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity J. Immunol. 163 1999 250 258
83. L.S. Peng Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3) J. Interferon Cytokine Res. 21 2001 709 720
84. V. Gafner An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties Int. J. Cancer 119 2006 2205 2212
85. R. Sommavilla Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12 Protein Eng. Des. Sel. 23 2010 653 661
86. N. Pasche The targeted delivery of IL17 to the mouse neo-vasculature enhances angiogenesis but does not reduce tumor growth rate Angiogenesis 2011 (Epub ahead of print)
87. C. Xuan Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma Blood 115 2010 2864 2871
88. T.H. Huang Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities J. Immunol. 179 2007 6881 6888
89. M.M. Mizokami Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies Hybrid Hybridomics 22 2003 197 207